Lomustine (CCNU)-Induced Pulmonary Fibrosis

  title={Lomustine (CCNU)-Induced Pulmonary Fibrosis},
  author={Enrico Tucci and P Verdiani and Simonetta di Carlo and Vincenzo Sforza},
  journal={Tumori Journal},
  pages={95 - 98}
A case of progressive pulmonary interstitial fibrosis following adjuvant lomustine (CCNU)-5-fluorouracil therapy for a colon carcinoma is reported. A close relationship between lomustine assumption and lung damage seems to emerge from the clinical, radiologic and histologic findings presented. On the basis of this experience and previous available data from literature, pulmonary toxicity must be regarded as a possible adverse effect of lomustine therapy. 

Figures from this paper

Lung toxicity of lomustine in the treatment of progressive gliomas

Findings support to limit lung function analyses on CCNU to patients with gliomas and pulmonary risk factors, however, all patients should be closely followed for clinical symptoms of pulmonary restriction.

Pleuropulmonary Changes Induced by Drugs in Patients with Hematologic Diseases

  • P. Camus
  • Medicine
    Pulmonary Involvement in Patients with Hematological Malignancies
  • 2010
Patients with hematologic diseases who are being treated with therapy drugs, or receive radiation therapy or blood transfusions may develop a host of potentially fatal infectious and noninfectious

Comparative aspects of pulmonary toxicity induced by cytotoxic agents with emphasis on lomustine, and a veterinary case report

The incidence and pathophysiology in human cancer patients of pulmonary toxicity induced by cytotoxic agents in general and by nitrosoureas in particular are discussed and a case report of a dog with pulmonary fibrosis, probably caused by chronic lomustine administration is presented.

Pulmonary toxicity of cytotoxic and immunosuppressive agents. A review.

Early detection of lung damage and immediate withdrawal of the responsible agent(s) are essential and Steroids may be of therapeutic value in some patients.

The pulmonary toxicity of nitrosoureas.

  • A. Smith
  • Medicine, Biology
    Pharmacology & therapeutics
  • 1989

Lomustine for treatment of mast cell tumors in cats: 38 cases (1999-2005).

Findings suggested that treatment with lomustine should be considered for cats with MCTs for which local treatment is not an option and was well tolerated.

Pulmonary involvement in patients with hematological malignancies

This book provides practical guidance on untangling complex diagnoses and selecting optimal treatments in patients with hematological malignancies.

Anticancer therapy and lung injury: molecular mechanisms

The review discusses chemotherapeutic agents that are reported to induce or associate with acute and/or chronic lung injury and whether such characteristics are inherently related to their antitumor effect or are collateral.



Fatal pulmonary toxic effects of lomustine.

A case in which lomustine treatment was followed by fatal pulmonary changes was reported, which is reported to be the first case of its kind in Europe.

Pulmonary disease as a complication of chlorozotocin chemotherapy.

Open-lung biopsy in one patient showed typical interstitial inflammation and early fibrosis, and excluded lymphangitic spread of tumor, and withdrew chlorozotocin.

Cytotoxic drug-induced lung disease.

Pulmonary fibrosis: A complication of 1,3‐bis(2‐chloroethyl)‐1‐nitrosourea (BCNU) therapy

A pediatric patient is reported who experienced fatal progressive pulmonary fibrosis as a complication of 1,3‐bis(2‐chloroethyl)‐1‐nitrosourea (BCNU) therapy as adjuvant therapy for a medulloblastoma.

Pulmonary fibrosis subsequent to high doses of CCNU for chronic myeloid leukemia

Two patients treated for chronic myeloid leukemia with high doses of CCNU developed a fatal pulmonary fibrosis and it is suggested that the pulmonary toxicity ofCCNU may be dose‐related.

Pulmonary toxicity of antineoplastic drugs.

This is a review of the antineoplastic drugs that are associated with pulmonary toxicity and clinical, laboratory, and pathological data are presented as useful information for practicing physicians.

Prediction of BCNU pulmonary toxicity in patients with malignant gliomas: an assessment of risk factors.

An equation has been generated that allows prediction of pulmonary toxicity during the course of therapy with BCNU with 80 per cent accuracy and should allow safe use and prevention of most of the serious pulmonary complications caused by this drug.

Cytotoxic drug-induced pulmonary disease: update 1980.

Review: diagnosis of chemotherapy lung.

The radiologist may be able to assess the probability of drug-induced lung disease by correlating radiographic and clinical data and information concerning concomitant or previous drug or radiation therapy.

Clinical trials with 1,3-bis(2-chloroethyl)-1-nitrosourea, NSC-409962.

Preliminary trials indicated that the following i.v. dose schedules were tolerable and comparable in toxicity; anti-tumor activity was noted in a variety of tumors in man and Hematopoietic toxicity was dose limiting and was delayed and prolonged after drug administration.